P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9

MLA

Saad Z Usmani, et al. “P864: A Phase 1 Study of Belantamab Mafodotin in Combination with Standard of Care in Newly Diagnosed Multiple Myeloma: An Interim Analysis of Dreamm-9.” HemaSphere, vol. 7, Aug. 2023. EBSCOhost, https://doi.org/10.1097/01.HS9.0000970360.06967.6b.

APA

Saad Z Usmani, Michał Mielnik, Ja Min Byun, Aránzazu Alonso Alonso, Al-Ola Abdallah, Mamta Garg, Hang Quach, Chang-Ki Min, Wojciech Janowski, Enrique Maria Ocio San Miguel, Katja Weisel, Albert Oriol, Irwindeep Sandhu, Paula Rodríguez-Otero, Karthik Ramasamy, Jacqueline Egger, Danaè Williams, Jie MA, Morrys Kaisermann, & Marek Hus. (2023). P864: A Phase 1 Study of Belantamab Mafodotin in Combination with Standard of Care in Newly Diagnosed Multiple Myeloma: An Interim Analysis of Dreamm-9. HemaSphere, 7. https://doi.org/10.1097/01.HS9.0000970360.06967.6b

Chicago

Saad Z Usmani, Michał Mielnik, Ja Min Byun, Aránzazu Alonso Alonso, Al-Ola Abdallah, Mamta Garg, Hang Quach, et al. 2023. “P864: A Phase 1 Study of Belantamab Mafodotin in Combination with Standard of Care in Newly Diagnosed Multiple Myeloma: An Interim Analysis of Dreamm-9.” HemaSphere 7 (August). doi:10.1097/01.HS9.0000970360.06967.6b.